Constellation Pharmaceuticals Investor Presentation — January 2020

Document content

Stellar Science, Breakthrough Medicine

January 13, 2020Developing Next -Generation

Epigenetic Treatments for

Corporate Overview2

This presentation and discussion contain “forward -looking statements” within the meaning of the Private Securities Litigation Re form Act of

1995 that involve substantial risks and uncertainties, including statements regarding the implications of preliminary or inte rimclinical data, the

development status of the Company’s product candidates, and the Company’s plans for future data presentations. All statements , other than

statements of historical facts, contained in this press release, including statements regarding the Company’s strategy, futur e operations,

future financial position, prospects, plans and objectives of management, are forward -looking statements. The words “anticipate, ” “believe,”

“continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “w ill,” “would” and similar

expressions are intended to identify forward -looking statements, although not all forward -looking statements contain these ident ifying words.

Any forward -looking statements are based on management’s current expectations of future events and are subject to a number of ri sks and

uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward -looking

statements. These risks and uncertainties include, but are not limited to, risks associated with Constellation’s ability to: obtain and maintain

necessary approvals from the FDA and other regulatory authorities; continue to advance its product candidates in clinical tri als; whether

preliminary or interim data from a clinical trial will be predictive of the final results of the trial; replicate in later cl inical trials positive results

found in preclinical studies and early -stage clinical trials of CPI -0610, CPI -1205, and CPI -0209; advance the development of its product

candidates under the timelines it anticipates, or at all, in current and future clinical trials; obtain, maintain, or protect intellectual property rights

related to its product candidates; manage expenses; and raise the substantial additional capital needed to achieve its busine ss objectives.

For a discussion of other risks and uncertainties, any of which could cause the Company’s actual results to differ from those contained in the

forward -looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other i mportant factors,

in the Company’s most recent filings with the Securities and Exchange Commission, including the Company’s Quarterly Report on Form 10 -Q